Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

RHEI Pharma to Market Oral Mucositis Treatment in China

publication date: Sep 30, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
RHEI Pharma has fleshed out its China marketing agreement with Access Pharmaceuticals for MuGard™, the latter company’s novel treatment for oral mucositis, a side effect of cancer treatment. MuGard is a ready-to-use mucoadhesive oral wound rinse and coating. RHEI specializes in bringing Western drugs to China. The original agreement between the two entities was signed almost three years ago. More details....

Stock Symbol: (OTCBB: ACCP)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors